Get started Log in

IXC — Invex Therapeutics Share News

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Market Cap
AU$7.89m
Enterprise Value
AU$3.87m
Revenue
AU$0.18m

Brief: Invex Therapeutics Requests Trading Halt
Thu 02:33
Brief: Invex Therapeutics Says Narelle Warren Resigns As CFO
07/11/2025 09:58
Brief: Invex Therapeutics' Negotiations Discontinued With Neurological Disease Therapeutics Development Co
30/09/2025 02:28
Australia's Invex Therapeutics falls as agreement talks fade
30/09/2025 02:15
Brief: Invex Therapeutics Seeks Trading Halt
23/09/2025 02:36
Australia's Invex Therapeutics drops on ending contract with Peptron
22/12/2023 04:04
Brief: Invex Therapeutics Ltd Says Invex And Peptron Mutually Terminate Manufacturing Agreement
21/12/2023 22:50
Brief: Invex Therapeutics Granted European Patent For Exenatide In Hydrocephalus
22/11/2023 01:16
Brief: Invex Therapeutics Proposes Capital Return To Shareholders Of A$14.0 Million
01/11/2023 08:36
Brief: Invex Therapeutics Ltd Issued Key Additional US Patent
23/08/2023 08:33
Brief: Invex Therapeutics Seeks Trading Halt
18/08/2023 24:28
Brief: Invex Therapeutics Announces Appointment Of Non-Executive Chair
03/07/2023 02:26
Australia's Invex Therapeutics eyes best day on European 'orphan drug' status
23/06/2023 02:38
Brief: Invex Therapeutics Announces Granting Of Orphan Drug Designation For Exenatide
23/06/2023 01:36
Australia's Invex Therapeutics climbs on neuro drug trial nod in France
21/04/2023 04:03
Brief: Invex Therapeutics Gets Regulatory Approval For IIH EVOLVE In France
21/04/2023 02:10
Brief: Invex Therapeutics Announces Ministry Of Health Approval For IIH EVOLVE Clinical Trial In Israel
20/04/2023 02:15
Brief: Invex Therapeutics Says Approval To Commence IIh Evolve Phase III Clinical Trial Received
19/03/2023 22:19
Brief: Invex Therapeutics Gets Approval For Paediatric Plan From The EMA
14/12/2022 01:16
Invex rises after neuro drug wins panel nod for late-stage trial in Australia
30/09/2022 06:55